Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine

1. Compounds of general formula (I)

in which

X stands for —O— or —NH—, and

R 1 stands for a methyl, ethyl, propyl or isopropyl group, and

R 2 and R 3 independently of one another, stand for hydrogen, a methyl or ethyl group, and

R 4 stands for a C 2 -C 6 -alkyl group or a C 3 -C 7 -cycloalkyl ring,

and salts, diastereomers and enantiomers thereof.

2. Compounds as claimed in claim 1 ,

characterized in that X stands for —O—,

and salts, diastereomers and enantiomers thereof.

3. The compounds as claimed in claim 1 ,

characterized in that R 1 stands for a methyl group,

and salts, diastereomers and enantiomers thereof.

4. The compounds as claimed in claim 1 ,

characterized in that R 2 stands for a methyl group,

and salts, diastereomers and enantiomers thereof.

5. The compounds as claimed in claim 1 ,

characterized in that R 3 stands for hydrogen or a methyl group,

and salts, diastereomers and enantiomers thereof.

6. The compounds as claimed in claim 1 ,

characterized in that R 4 stands for a methyl or ethyl group or for a cyclopropyl ring,

and salts, diastereomers and enantiomers thereof.

7. The compounds of general formula (I) as claimed in claim 1 , in which

X stands for —O— or —NH—, and

R 1 stands for a methyl group, and

R 2 stands for a methyl group, and

R 3 stands for hydrogen or a methyl group, and

R 4 stands for a methyl or ethyl group or for a cyclopropyl ring,

and salts, diastereomers and enantiomers thereof.

8. A method of production of compounds of general formula (Ia), comprising at least one of steps a)-h)

a) Oxidation of a compound of formula (IVd)

to the sulfoxide of formula (IVc)

b 1 ) Direct imination of the sulfoxide of formula (IVc)

to a protected sulfoximine of formula (IVa)

or

b 2 ) Imination of the sulfoxide of formula (IVc)

to an unprotected sulfoximine of formula (IVb)

and subsequent introduction of the protective group to a compound of formula (IVa)

c) Reduction of the compound of formula (IVa)

to a compound of formula (IV)

d) Functionalization of the 4-position of 2,4-dichloro-5-iodo-pyrimidine (VII)

by reaction with a mono-protected diol of formula (VI)

with formation of an intermediate of formula (Va)

e) Production of the 5-CF3 intermediate (V)

from the 5-I intermediate (Va)

f) Coupling of the compounds of formula (IV)

and (V)

to form the intermediate of formula (III)

g) Cleavage of the protective group PG of a compound of formula (III)

with formation of (II)

h) Cleavage of the protective group on the sulfoximine of formula (II)

with formation of (Ia)

characterized in that the substituents R 1 , R 2 , R 3 and R 4 have the meanings given in general formula (I) of claim 1 .

9. A method of production of compounds of general formula (Ib), comprising at least one of steps a)-f)

a) Oxidation of a compound of formula (IVd)

to the sulfoxide of formula (IVc)

b 1 ) Direct imination of the sulfoxide of formula (IVc)

to form a protected sulfoximine of formula (IVa)

or

b 2 ) Imination of the sulfoxide of formula (IVc)

to form an unprotected sulfoximine of formula (IVb)

and subsequent introduction of the protective group to a compound of formula (IVa)

c) Reduction of the compound of formula (IVa)

to a compound of formula (IV)

d) Functionalization of the 4-position of 2,4-dichloro-5-trifluoromethyl-pyrimidine (VIIb)

by reaction with an amine of formula (VIa)

with formation of an intermediate of formula (Vb)

e) Coupling of the compounds of formula (Vb)

and (IV)

to form the intermediate of formula (IIb)

f) Cleavage of the protective group on the sulfoximine of formula (IIb)

with formation of (Ib)

characterized in that the substituents R 1 , R 2 , R 3 and R 4 have the meanings given in general formula (I) of claim 1 .

10. The compounds as claimed in claim 1 for use as medicinal products.

11. A pharmaceutical formulation containing a compound as claimed in claim 1 .

12. A method for treating cancer comprising administering an effective amount of a compound as claimed in claim 1 to a patient in need thereof.

13. A compound as claimed in claim 1 , wherein the compound is (RS)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide.

14. A compound as claimed in claim 1 , wherein the compound is (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide.

15. A compound as claimed in claim 1 , wherein the compound is (S)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide.

16. The method as claimed in claim 12 , wherein the cancer is cervical cancer.

17. The method as claimed in claim 16 , wherein the compound is (RS)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide.

18. The method as claimed in claim 16 , wherein the compound is (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide.

19. The method as claimed in claim 16 , wherein the compound is (S)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide.